Published in Medical Letter on the CDC and FDA, July 1st, 2001
The panel convened by the U.S. Food and Drug Administration (FDA) had been asked to consider whether prescription sales should be permitted for GHB - gamma hydroxy butyrate - under the brand name Xyrem.
The committee voted 6-3 that the manufacturer has shown that the drug is useful in treating cataplexy, a complication that can cause people to suddenly collapse when their muscles lose strength.
The vote, in effect, endorses sales of the drug. The FDA is not...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.